{"classes":[{"categories":[{"measurements":[{"comment":"AUC(0 to t) could not be calculated as the values were below limit of quantification.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"AUC(0 to t) could not be calculated as the values were below limit of quantification.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"AUC(0 to t) could not be calculated as the values were below limit of quantification.","groupId":"OG002","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 2\\*10\\^8 plaque forming unit (PFU) once weekly for 4 weeks as an intravenous (IV) push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG000","title":"Part 1A PF-07263689 2*10^8 PFU"},{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 6\\*10\\^8 PFU once weekly for 4 weeks as an IV push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG001","title":"Part 1A PF-07263689 6*10^8 PFU"},{"description":"Participants with any advanced or metastatic solid tumor indications with approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents were administered PF-07263689 at a dose 20\\*10\\^8 PFU once weekly for 4 weeks as an IV push. Participants were followed up for up to 90 days post-last dose of study treatment. Participants were followed up for survival until death, withdrawal of consent, or end of the study.","id":"OG002","title":"Part 1A PF-07263689 20*10^8PFU"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Blood viral load Kinetics Analysis Set included all enrolled participants treated who did not have protocol deviations influencing viral load kinetics assessment, and had sufficient information to estimate at least 1 of the parameters of interest. Data is not reported for Part 1b as no participants were enrolled and data was not collected.","reportingStatus":"POSTED","timeFrame":"Day 1 (pre-dose, 0.5, 1, 4, 8 hours post-dose), Day 2, Day 3, Day 4, Day 8 (pre-dose, 0.5, 1, 4, 8 hours post-dose), Day 9, Day 10, Day 15 and 22 (pre-dose and 4 hours post-dose)","title":"Part 1: Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration of PF-07263689 in Blood","type":"SECONDARY","unitOfMeasure":"Hours*copies per milliliter"}